Sure, thank you.
In terms of provisions that we would not want to adopt from the U.S.-Korea agreement, the intellectual property rights provisions that I refer to, data exclusivity and so-called linkage provisions--I know those are complicated terms—that would push up the price of drugs, are driven by the brand name manufacturers mainly based in the United States. They have been pushed through U.S. bilateral free trade agreements, and somewhat through European, but up until now, not by Canada.
Canada is in a somewhat different situation. As I mentioned earlier, and one of the committee members mentioned, drug prices are a driver of costs in our system for provincial governments in particular, but also for consumers and employers who pay out of pocket for those higher prices.